Christopher G. Paulraj
12 IP cases indexed. Covers patent matters.
Cases Presided Over
12 cases indexed | Page 1 of 1
Syngenta Crop Protection AG v.Inflexion Point Technologies, LLC
The PTAB denied Syngenta’s request for rehearing of its post‑grant review denial on patent 12,102,027. The Board concluded the petitioner failed to demonstrate any abuse of discretion in the original decision.
MIM Software Inc. et al. v.Progenics Pharmaceuticals, Inc. et al.
The PTAB denied MIM Software's request to institute IPR against Progenics Pharmaceuticals regarding a medical image analysis patent. The denial was based on Petitioner's failure to properly construe the key term 'risk map,' proposing multiple ambiguous definitions without adequate justification.
MIM Software Inc. et al. v.Progenics Pharmaceuticals, Inc. et al.
The PTAB denied MIM Software's request to review claims in Progenics' medical image analysis patent. The denial was based on Petitioner's failure to provide a clear, single claim construction for key terms like 'risk map.'
MIM Software Inc. et al. v.Progenics Pharmaceuticals, Inc. et al.
The PTAB denied MIM Software's IPR against Progenics Pharmaceuticals because the petition failed to provide adequate claim construction rationale. The Board found that Petitioner’s proposed constructions for 'risk indices' were too ambiguous and insufficiently supported by prior art.
MIM Software Inc. et al. v.EXINI Diagnostics AB, Inc. et al.
MIM Software and EXINI Diagnostics settled their inter partes review, leading the PTAB to terminate the proceeding and keep the settlement agreement confidential.
Embody, Inc. et al. v.LifeNet Health
Embody and Zimmer Biomet successfully secured institution in this IPR against LifeNet Health's '223 patent. The Board found a reasonable likelihood that claims related to collagen scaffolds with specific FFT analysis characteristics are unpatentable over prior art references like Huang2 and Lee.
MIM Software Inc. et al. v.EXINI Diagnostics AB, Inc. et al.
MIM Software Inc. successfully petitioned to institute IPR against EXINI Diagnostics AB, Inc.'s patent (11941817) on grounds of anticipation and obviousness. The Board found reasonable likelihood that the claims are unpatentable based on prior art references like Renisch and Zhao.
Clearwater Paper Corporation v.--
The PTAB granted institution of IPR for Clearwater Paper Corporation against Graphic Packaging International LLC, challenging claims related to biodegradable paper cups based on prior art references Cleveland and Nakagawa.
Embody, Inc. et al. v.LifeNet Health
Embody, Inc. challenged LifeNet Health's tissue engineering patent (11318227) based on anticipation and obviousness. The PTAB instituted trial on all eight claims after finding merit in the petitioner’s arguments regarding fiber alignment and FFT analysis.
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS, INC. successfully secured institution of its IPR against Helsinn Healthcare S.A.'s patent (9186357) for anti-emetic agents. The Board found a reasonable likelihood that several claims would be unpatentable over prior art, specifically regarding the combination of triple-drug CINV treatment and superior NK antagonists.
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS successfully convinced the PTAB to institute IPR proceedings against Helsinn Healthcare S.A.'s patent covering anti-emetic agents for oncology treatment. The Board found a reasonable likelihood that numerous claims would be unpatentable under 35 U.S.C. § 103 based on prior art references.
Syngenta Crop Protection AG v.Inflexion Point Technologies, LLC
Syngenta Crop Protection AG's petition to invalidate Inflexion Point Technologies' patent was denied by the PTAB. The Board found insufficient evidence of anticipation or obviousness across multiple grounds, rejecting all challenges including enablement.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.